Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 296 of 296 entries
View as:

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Phase: N/A Priority: Normal
NCT ID: NCT02039726 Org: User:
Start: 05/31/14 End: 09/08/20 Due: 09/08/21

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Phase: N/A Priority: Normal
NCT ID: NCT00791258 Org: User:
Start: 11/30/08 End: 09/30/09 Due: 09/30/10

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02452424 Org: User:
Start: 07/02/15 End: 10/12/18 Due: 10/12/19

An Open Study Assessing the Safety and Tolerability of U3-1784

Phase: N/A Priority: Normal
NCT ID: NCT02690350 Org: User:
Start: 02/29/16 End: 02/28/17 Due: 02/28/18

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Phase: N/A Priority: Normal
NCT ID: NCT06174987 Org: User:
Start: 01/05/24 End: 08/03/26 Due: 08/03/27

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Phase: N/A Priority: Normal
NCT ID: NCT04526704 Org: User:
Start: 10/20/20 End: 07/07/23 Due: 07/07/24

Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)

Phase: N/A Priority: Normal
NCT ID: NCT02951039 Org: User:
Start: 02/21/17 End: 10/15/20 Due: 10/15/21

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06244485 Org: User:
Start: 02/16/24 End: 11/01/28 Due: 11/01/29

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03614455 Org: User:
Start: 07/13/18 End: 10/01/18 Due: 10/01/19

A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

Phase: N/A Priority: Normal
NCT ID: NCT02473627 Org: User:
Start: 05/31/15 End: 07/31/15 Due: 07/31/16

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT04644237 Org: User:
Start: 03/19/21 End: 08/23/24 Due: 08/23/25

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00147758 Org: User:
Start: 06/30/04 End: 08/31/06 Due: 08/31/07

Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00789750 Org: User:
Start: 04/30/09 End: 07/31/12 Due: 07/31/13

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01211483 Org: User:
Start: 09/30/10 End: 11/23/13 Due: 11/23/14

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT03030066 Org: User:
Start: 01/19/17 End: 08/31/26 Due: 08/31/27

Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00143520 Org: User:
Start: 12/31/04 End: 12/31/05 Due: 12/31/06

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06644755 Org: User:
Start: 11/14/24 End: 11/30/28 Due: 11/30/29

Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017

Phase: N/A Priority: Normal
NCT ID: NCT00881569 Org: User:
Start: 03/31/09 End: 09/30/11 Due: 09/30/12

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01755767 Org: User:
Start: 12/27/12 End: 07/31/17 Due: 07/31/18

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT03552029 Org: User:
Start: 12/12/18 End: 04/01/21 Due: 04/01/22

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Phase: N/A Priority: Normal
NCT ID: NCT06644768 Org: User:
Start: 10/30/24 End: 04/30/30 Due: 04/30/31